COVID-19 Vaccination Programme Update
Updated advice regarding Astra Zeneca Vaccine for those aged <30
You will be aware that the MHRA and JCVI held a briefing on Wednesday April 7th on the Oxford/AstraZeneca vaccine following reports of a very rare blood clotting problem affecting a small number of people who have had this vaccine. During the briefing the MHRA and JCVI stated that the clinical advice for those aged 30 and under will change regarding first doses of the AZ vaccine.
We understand that patients may have questions regarding the implications of the new advice. To address some of these questions we would like to draw your attention to updated guidance that Public Health England published today. This guidance provides clarity on a number of practical issues that you may be considering as a result of the new advice from the MHRA and JCVI. This new guidance includes information on what we know of the very rare blood clotting problem to date, practical advice on the first and second dose of the COVID-19 vaccine for patients under 30 going forward, information about risk, benefit and age and information about contraindications and cautions to receiving an AZ vaccine at any age.
Additional information can be found at
As we receive any further updates we will post them to this section of our website.
Published: Apr 8, 2021
By using this site, you agree that we may store and access cookies on your device. Find out about our cookies.
Functional Cookies are enabled by default at all times so that we can save your preferences for cookie settings and ensure site works and delivers best experience.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.